Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.005
Sell
RSI(14)
34.797
Neutral
STOCH(KDJ)(9,3,3)
7.167
Oversold
ATR(14)
0.148
High Vlolatility
CCI(14)
-114.350
Sell
Williams %R
95.556
Oversold
TRIX(12,20)
-0.663
Sell
StochRSI(14)
61.035
Buy
Search
Evaxion Biotech A/S
EVAXAdd to Watchlist
2.820USD
+0.030+1.07%
Close 07-31 16:00（ET）Quotes delayed by 15 min
23.52MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.07%
5 Days
-4.73%
1 Month
-9.03%
6 Months
-11.32%
Year to Date
-40.88%
1 Year
+5.22%
Key Figures
2.800Open
2.880High
15.52KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.19%Turnover Ratio
2.830Prev. Close
2.800Low
29.16KTurnover
LossP/E Static
1.78P/B
0.00%Div Yield TTM
-39.92%ROA
12.15052wk High
1.34Volume Ratio
-10.57MNet Profit
8.34MShares
-0.2080EPS TTM
0.26Beta
-82.85%ROE
2.07052wk Low
2.83%Amplitude
100.00%Gross Margin
23.52MMarket Cap
-2.79Reward/Risk
6.10%Risk Rate
TradingKey Stock Score of Evaxion Biotech A/S
Currency: USD Updated: 2026-07-31Key Insights
Evaxion Biotech A/S's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 160 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.25.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evaxion Biotech A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Evaxion Biotech A/S Highlights
StrengthsRisks
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 10212.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.53M.
Undervalued
The company’s latest PE is -13.56, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 323.61K shares, increasing 1.65% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
11.250
Target Price
+296.13%
Upside Space
Evaxion Biotech A/S News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
4
analysts
Buy
Current Rating
11.250
Target Price
+296.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Evaxion Biotech A/S
EVAX
4
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
2.836
Sell
MA10
2.919
Sell
MA20
3.040
Sell
MA50
3.379
Sell
MA100
3.721
Sell
MA200
4.336
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Evaxion Biotech A/S Info
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Ticker SymbolEVAX
CompanyEvaxion Biotech A/S
CEO
Websitehttps://evaxion.ai/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Evaxion Biotech A/S (EVAX)?
The current price of Evaxion Biotech A/S (EVAX) is 2.81.
What is the symbol of Evaxion Biotech A/S?
The ticker symbol of Evaxion Biotech A/S is EVAX.
What is the 52-week high of Evaxion Biotech A/S?
The 52-week high of Evaxion Biotech A/S is 12.15.
What is the 52-week low of Evaxion Biotech A/S?
The 52-week low of Evaxion Biotech A/S is 2.07.
What is the market capitalization of Evaxion Biotech A/S?
The market capitalization of Evaxion Biotech A/S is 23.44M.
Is Evaxion Biotech A/S (EVAX) currently rated as Buy, Hold, or Sell?
According to analysts, Evaxion Biotech A/S (EVAX) has an overall rating of Buy, with a price target of 11.25.
What is the Earnings Per Share (EPS TTM) of Evaxion Biotech A/S (EVAX)?
The Earnings Per Share (EPS TTM) of Evaxion Biotech A/S (EVAX) is -1.20.